By Iris Vander Pluym on 10.11.15
Here we have a Washington Post story highlighting a recent "scandal": Martin Shkreli, CEO of Turing Pharmaceuticals, raised the price of an off-patent AIDS drug by over 5,000 percent. The Post reports:
The major pharmaceutical and biotech industry groups have portrayed Shkreli's actions as totally repugnant and the work of just one company, acting alone, with a flippant young chief executive who doesn't reflect the broader values, practices, or trends of other companies.
Read More